DADA
Diisopropylamine Dichloroacetate (DIPA-DCA)
DADA (Diisopropylamine Dichloroacetate (DIPA-DCA)) is a metabolic & fat loss research compound. The dichloroacetate moiety inhibits pyruvate dehydrogenase kinase (PDK), reactivating pyruvate dehydrogenase — pushing cells out of glycolysis back into mitochondrial glucose oxidation (reversing the Warburg shift); the diisopropylamine carrier adds a lipotropic/circulatory angle.
DADA quick facts
| Reported research dose (Oral) | 50mg-200mg |
| Route | Either |
| Frequency | 1x Daily AM · 5 On 2 Off or Daily |
| Half-life | Short–moderate |
| Forms | Oral, Injectable |
| Evidence level | Human (older clinical use) + DCA research |
| Other forms available | Injectable — dosed differently |
Re-routes metabolism at the mitochondria. DCA's peripheral-neuropathy risk at high or chronic doses is the real caution — pulse it, don't live on it.
How DADA works
The dichloroacetate moiety inhibits pyruvate dehydrogenase kinase (PDK), reactivating pyruvate dehydrogenase — pushing cells out of glycolysis back into mitochondrial glucose oxidation (reversing the Warburg shift); the diisopropylamine carrier adds a lipotropic/circulatory angle.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get DADA
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for DADA
Graded by what exists behind each claim.
✅ Clinically validated
- No trials of this compound. Its active moiety, dichloroacetate, has real human data — decades of use in congenital lactic acidosis and mitochondrial disease, and small trials in glioblastoma and pulmonary hypertension.
- That literature also carries a clear limiting finding: dose-dependent peripheral neuropathy, which is the reason DCA has not progressed as a chronic therapy despite consistent mechanistic interest.
📊 Correlative data
- Very limited use, mostly in metabolic and oncology-adjacent research contexts. The DCA experience is the relevant real-world record, and it is one where the side effect emerged on long-term dosing rather than short.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- The dichloroacetate portion inhibits pyruvate dehydrogenase kinase, which releases the brake on pyruvate dehydrogenase — pushing pyruvate into the mitochondria for oxidation rather than into lactate.
- This reverses the Warburg shift, the glycolytic metabolism cancer cells favor, and restoring mitochondrial oxidation restores their apoptotic sensitivity. That is the oncology rationale and it is mechanistically sound.
- The neuropathy is mechanism-linked, not incidental — peripheral nerves are sensitive to the metabolic shift, and it is the predictable cost of forcing substrate flux in every tissue at once.
What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What DADA actually does
The active half of this compound is dichloroacetate, and it does one thing at one enzyme: it inhibits pyruvate dehydrogenase kinase. Pyruvate dehydrogenase is the gate between glycolysis and the mitochondrion — it converts pyruvate to acetyl-CoA, the step that commits a carbon skeleton to oxidation rather than to lactate. The kinase switches that gate off by phosphorylating it. Inhibit the kinase and the gate stays open James 2017.
Which makes this one of the very few compounds in the Vault whose mechanism is a single, named, well-characterized enzyme step. Most pages here have to reason about receptors with unknown occupancy. This one has a substrate, a product, and a phosphorylation site.
What the reactivation does downstream, measured in cells. DADA promotes the conversion of pyruvate to acetyl-CoA by inhibiting pyruvate dehydrogenase kinase, which raises oxidative phosphorylation and mitochondrial fitness Bi 2026. In tumor cells it significantly inhibited lactate production and promoted apoptosis, with a fall in mitochondrial membrane potential in combination treatment Wei 2024. Restoring mitochondrial oxidation in a cell that had been running glycolytically restores its sensitivity to apoptosis — that is the entire oncology rationale, and it is mechanistically clean.
The diisopropylamine half is the counter-ion, and it deserves one honest sentence. The published work on this specific salt attributes the biological effects to the dichloroacetate moiety and studies the compound as a PDK inhibitor Wei 2024Bi 2026. Claims that the amine adds a separate lipotropic or circulatory action are not supported by the papers that study this salt, and this page will not repeat them.
The mechanism has a measurable signature that is not weight. Reactivating pyruvate dehydrogenase moves flux out of lactate. Hyperpolarized magnetic resonance is the technique that can watch that conversion happen in a living animal in real time — the same method used to show increased pyruvate-to-acetyl-CoA handling with another metabolic agent Savic 2021. The readout for this drug is a carbon flux, not a body composition scan, and that is why the fat-loss framing sits so awkwardly on it.
Cell, rodent, human — and where it stops
Step one, cells, and the data are recent and specific to this salt. Diisopropylamine dichloroacetate inhibited lactate production and promoted apoptosis in non-small cell lung cancer cells; combined with pemetrexed it inhibited proliferation and promoted apoptosis significantly more than either alone (P<0.05), with a fall in mitochondrial membrane potential in the combination arm; combined with radiotherapy it induced markedly more DNA damage Wei 2024.
Step two, mice, and this is where the story stops being about the tumor cell. In Lewis lung carcinoma models, the triple combination of radiotherapy, anti-PD-1 antibody and DADA outperformed radiotherapy plus anti-PD-1 (P<0.05), and the mechanism appeared to run through an increased number of CD3+ T cells — the authors attribute it to reduced local lactic acid in the tumor microenvironment Wei 2024. Separate 2026 work found DADA promotes accumulation of progenitor exhausted CD8+ T cells, improves the efficacy of PD-1 blockade, and confers stemness on CAR-T cells expanded in vitro Bi 2026.
Say plainly what that means for this page. The modern literature on this exact molecule is immuno-oncology, not fat loss. The mechanism being investigated is metabolic reprogramming of T cells and of the tumor microenvironment. Nothing in it is about body composition in a healthy adult, and a reader should know that the compound's active research question is a different question from the one the shelf implies.
Step three, humans — and the human record belongs to dichloroacetate rather than to this salt. DCA has been used clinically in inherited mitochondrial disorders causing lactic acidosis, in pulmonary hypertension and in solid tumors, and the main clinically limiting toxicity is reversible peripheral neuropathy James 2017. In humans, toxicity has so far been limited to reversible effects on the nervous system and the liver Stacpoole 2011.
The obstacle, and it is unusually well documented. Fifty years of experimentation have left DCA's therapeutic future uncertain; without adequate clinical trials and regulatory approval it has been introduced off-label in alternative-medicine clinics in Canada, Germany and elsewhere, and the lack of well-planned trials plus its use by people without medical training has discouraged consideration by the scientific community; much of the supporting publication record is individual case reports Koltai 2024. That is a review written by someone sympathetic to the compound, which makes it the most useful summary available.
DADA pharmacokinetics — how much of it actually gets in
The card says short to moderate. That is the one thing this drug's half-life is not, because dichloroacetate inhibits its own elimination — the half-life grows with use. This is the most important pharmacokinetic fact about the compound and almost nobody selling it mentions it.
The enzyme that clears it is the enzyme it destroys. The first step in DCA metabolism is conversion to glyoxylate, catalyzed by glutathione transferase zeta 1 — and DCA is a mechanism-based inactivator of that same enzyme James 2017. It is a suicide inhibitor of its own clearance route. In every studied species including humans, DCA has the property of inhibiting its own metabolism upon repeat dosing, altering its pharmacokinetics James 2017, which is described elsewhere as delayed plasma clearance on repeated exposure Stacpoole 2011.
What follows, and it inverts normal dosing intuition. A drug whose clearance falls with exposure accumulates non-linearly: the fifth dose produces a higher peak than the first even at an identical milligram amount, and the plateau keeps rising rather than settling. Pulsing it is not a stylistic preference — it is the only schedule that respects the enzymology, because a washout gives GSTZ1 time to be resynthesized. The rate of that inactivation is influenced by age, GSTZ1 haplotype and cellular chloride concentration James 2017, and age and haplotype markedly affect the toxicokinetics in humans and rodents Stacpoole 2011.
The second consequence is a metabolic one, and it explains the neuropathy. GSTZ1 is a bifunctional enzyme — it is also maleylacetoacetate isomerase, which catalyzes the penultimate step of phenylalanine and tyrosine catabolism. Inactivating it therefore causes accumulation of potentially toxic tyrosine intermediates Stacpoole 2011. The dose-limiting toxicity is not a mysterious off-target effect; it is the predictable consequence of poisoning an enzyme that had a second job.
Routes. DCA salts are absorbed orally and the human clinical experience is oral James 2017. There is no advantage to an injection here — the compound is a small carboxylic acid, not a peptide, so it does not face the proteolytic barrier that forces every other compound in this cohort into a syringe. First-pass metabolism is hepatic and is exactly the step that self-inactivates, which is why oral exposure rises across a course rather than staying flat.
What would have to be true, and how you would know it was not
Three predictions with markers and windows. The third is the one that argues for a schedule the market does not use.
1. Thiamine demand should rise, and nobody has ever checked it. Pyruvate dehydrogenase is a thiamine-dependent enzyme — its E1 subunit requires thiamine pyrophosphate as a cofactor. Forcing the complex into sustained activity increases cofactor turnover. Extrapolated from the enzymology and clearly labeled as such: predict that vitamin B1 falls measurably over 8 to 12 weeks of regular use, and that a marginal thiamine status blunts the compound's effect because the enzyme cannot run without it. This has never been measured in a person on DCA, it is a cheap assay, and it is the single most testable new idea on this page.
2. Liver enzymes and uric acid are the safety pair. Human toxicity has been limited to reversible effects on the nervous system and the liver Stacpoole 2011, and the tyrosine-pathway intermediates that accumulate when GSTZ1 is inactivated are handled hepatically James 2017. Prediction: a CMP at baseline and at 6 weeks shows transaminases within range on a pulsed schedule and drifting upward on a continuous one, with uric acid as the second line on the same tube. Continuous dosing is the condition that should separate the two arms.
3. Against continuous use: the neuropathy is a cumulative-exposure phenomenon, so the falsifiable claim is about schedule rather than dose. The clinically limiting toxicity is reversible peripheral neuropathy James 2017, and it emerged on long-term rather than short dosing. Because clearance falls with exposure, cumulative concentration on a fixed daily dose climbs even when the dose does not. Prediction: symptoms appear as a function of weeks of continuous exposure, not of milligrams per dose, and a pulsed schedule with real washouts reaches the same acute metabolic effect without approaching the same cumulative one. Distal numbness or tingling is the observable, it is reversible if acted on, and the thing that will fool you is attributing it to training or to a position rather than to the compound.
What nobody has tested yet
Four experiments, two of which are one blood draw each.
Nobody has genotyped a self-experimenter for GSTZ1. Haplotype markedly affects the toxicokinetics Stacpoole 2011 and the rate at which the enzyme is inactivated James 2017. That means the same dose is a different exposure in different people by a predictable, genotype-determined amount — and it is one of the very few places in this whole catalog where a genetic test would actually change a dose. No such stratification exists outside the clinical mitochondrial-disease literature.
Nobody has measured thiamine status on DCA. See the prediction above; the assay is standard, the mechanism is direct, and the literature is silent.
Whether the immunometabolic effects appear at doses a person would take. The T-cell stemness and PD-1-blockade results are mouse and in-vitro work at oncology exposures Bi 2026Wei 2024. Whether a lower, intermittent human dose does anything measurable to lymphocyte subsets is answerable with flow cytometry on a routine blood sample and has not been asked.
What it does to lactate in an exercising human. The mechanism is a shift out of lactate production, and the technology to watch that flux non-invasively exists Savic 2021. A simple version needs no imaging at all: a standardized exercise test with serial fingertip lactate, before and after a course. Lower lactate at matched workload would be direct target engagement in a person, and nobody has published it.
DADA — its own safety story, not its class's
This compound's own risk is a nerve risk and a cumulative one, and its cause is understood well enough to be managed rather than feared.
Peripheral neuropathy is the dose-limiting toxicity in humans. It is described as the main clinically limiting toxicity and as reversible James 2017. Reversible is the operative word and it is conditional on stopping: the mechanism is accumulation, so continuing through early symptoms is the one decision that converts a reversible problem into a longer one.
The carcinogenicity question, answered in both directions. High doses in rodents can produce liver cancer, and there is no evidence that DCA is a human carcinogen James 2017. Separately, DCA is an environmental contaminant — a by-product of water chlorination and a metabolite of industrial solvents — which is why it occupies an unusual position at the interface between environmental toxicology and clinical medicine Stacpoole 2011. Both of those facts get quoted selectively by whichever side is arguing.
Age changes the kinetics, not just the tolerance. Age and GSTZ1 haplotype markedly affect toxicokinetics in humans Stacpoole 2011, and younger people clear DCA differently from older ones. A dose derived from adult clinical experience is not transferable across age groups by body weight.
The honest position on the oncology literature, which is where this compound's reputation comes from. The favorable results are real and they are preclinical or anecdotal; the compound has been used off-label in clinics without approval, largely on the strength of case reports, and that pattern has actively discouraged the research community from engaging with it Koltai 2024. Anyone taking this for a metabolic goal should know that they are borrowing a safety profile from a cancer literature, and that the people who wrote that literature are asking for trials rather than declaring victory.
Sources read for this page
- James MO, et al. Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. Pharmacology and Therapeutics 2017 · PMID 27771434
- Stacpoole PW. The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?. Environmental Health Perspectives 2011 · PMID 20920954
- Koltai T. Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts. Pharmaceuticals (Basel) 2024 · PMID 38931411
- Wei M, et al. The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment. Frontiers in Oncology 2024 · PMID 39267851
- Bi M, et al. DADA Enhances CD8+ T Cell Stemness to Improve Anti-Tumor Immunity and Immunotherapy Efficacy. Advanced Science 2026 · PMID 41758776
- Savic D, et al. Hyperpolarized magnetic resonance shows that the anti-ischemic drug meldonium leads to increased flux through pyruvate dehydrogenase in vivo resulting in improved post-ischemic function in the diabetic heart. NMR in Biomedicine 2021 · PMID 33458907
DADA — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signaling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signaling reasoning above.
- Pregnancy — uncharacterized.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalog should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
DADA — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What DADA moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — DADA in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside DADA
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
DADA — frequently asked questions
What is DADA?
DADA (Diisopropylamine Dichloroacetate (DIPA-DCA)) is a metabolic & fat loss research compound. The dichloroacetate moiety inhibits pyruvate dehydrogenase kinase (PDK), reactivating pyruvate dehydrogenase — pushing cells out of glycolysis back into mitochondrial glucose oxidation (reversing the Warburg shift); the diisopropylamine carrier adds a lipotropic/circulatory angle.
Is the full DADA protocol on this page?
The reported research dose is on this page, along with how DADA works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of DADA?
DADA has an approximate half-life of Short–moderate, which is part of what determines how often it's dosed.
What forms does DADA come in?
DADA is available as: Oral, Injectable.
What's the evidence behind DADA?
Current evidence level: Human (older clinical use) + DCA research. DADA is offered for research purposes only and is not an approved medicine.
What DADA is used for
DADA appears under 1 goal in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.